Broncus Holding Corporation
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BRNHF research report →
Companywww.broncus.com
Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker.
- CEO
- Hong Xu
- IPO
- 2022
- Employees
- 200
- HQ
- Hangzhou, CN
Price Chart
Valuation
- Market Cap
- $42.13M
- P/E
- -3.35
- P/S
- 374.28
- P/B
- 0.40
- EV/EBITDA
- -1.47
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -1585.06%
- Op Margin
- -14017.85%
- Net Margin
- -10273.01%
- ROE
- -11.54%
- ROIC
- -16.26%
Growth & Income
- Revenue
- $8.13M · -20.71%
- Net Income
- $-15,303,000 · 45.52%
- EPS
- $-0.03 · 46.09%
- Op Income
- $-19,791,000
- FCF YoY
- 61.53%
Performance & Tape
- 52W High
- $0.08
- 52W Low
- $0.08
- 50D MA
- $0.08
- 200D MA
- $0.08
- Beta
- 1.18
- Avg Volume
- 5.32K
Get TickerSpark's AI analysis on BRNHF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BRNHF Coverage
We haven't published any research on BRNHF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BRNHF Report →